H5N1 Vaccine Induces Protective Antibodies in Humans
Author Information
Author(s): Howard M. Keith, Sabarth Nicolas, Savidis-Dacho Helga, Portsmouth Daniel, Kistner Otfried, Kreil Thomas R., Ehrlich Hartmut J., Barrett P. Noel
Primary Institution: Baxter BioScience
Hypothesis
Can passive transfer of H5N1 vaccine-induced immune sera protect against lethal H5N1 virus challenge in mice?
Conclusion
The Vero cell culture-derived H5N1 vaccine is likely to be effective in a pandemic situation, as it induces protective neutralizing antibodies.
Supporting Evidence
- Passive transfer of immune sera provided dose-dependent protection against lethal H5N1 virus challenge.
- Complete protection was observed with serum neutralizing antibody titers of 1:16 or higher.
- Human immune sera required repeated doses to achieve complete protection.
- Neutralizing antibody titers correlated with protection from severe H5N1 challenge.
Takeaway
Scientists tested a vaccine that helps protect against a dangerous bird flu by giving mice blood from vaccinated people, and it worked well!
Methodology
Mice were injected with immune sera from vaccinated humans and challenged with a lethal dose of H5N1 virus to assess protection.
Potential Biases
Potential bias due to funding from Baxter Bioscience, the vaccine manufacturer.
Limitations
The study's findings may not directly translate to humans due to the differences between species and the low incidence of H5N1 infections.
Participant Demographics
The study involved 583 participants, primarily adults, who received the H5N1 vaccine.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website